title: Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption.
abstract: OBJECTIVE
  The aims of the present study were to determine if metabolic abnormalities and cytokine derangements are modified in HIV-1-infected patients after 12 months on treatment interruption (TI).
  
  
  METHODS
  The design of this study was prospective randomized study.
  
  
  METHODS
  Longitudinal multicenter study in HIV-1-infected patients with a 12-month follow-up. Patients on stable highly active antiretroviral therapy, with CD4 count >600/microL and HIV RNA <50 copies/mL for at least 6 months, were randomized to interrupt therapy or continue ongoing highly active antiretroviral therapy. Lipids (total cholesterol, triglycerides), apoproteins (A1, B, and E), and adipocytokines (leptin, adiponectin, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, Interleukin-6, Interleukin-8, and tumor necrosis factor-alpha) were measured at baseline and at month 12. Multiplex suspension bead array immunoassay was performed using the Luminex 100 analyzer to identify protein expression in plasma.
  
  
  RESULTS
  Patients who underwent TI (n = 19) had a significant decrease in median cholesterol levels (P < 0.001), while median triglyceride levels remained unchanged. There was a significant decrease in Apo-A1 levels (P = 0.048) and Apo-B levels (P < 0.001) and an increase in tumor necrosis factor-alpha levels (P = 0.034). Given the greater decrease in Apo-B, the ratio Apo-A1/Apo-B increased after 12 months of TI (from 3.4 to 5.1, P = 0.008). We did not find significant variations in leptin or adiponectin levels. In patients who continued on highly active antiretroviral therapy (n = 18), there were no significant changes in any of the measured parameters.
  
  
  CONCLUSIONS
  The lipid profile and apoproteins levels change toward a less atherogenic profile after TI, arguing against a lipid-mediated mechanism to explain the increased cardiovascular risk in patients who interrupt treatment.
authors.affiliation: Laboratorio de Inmuno-Biología Molecular, Hospital General Universitario "Gregorio Marañón," Madrid, Spain.
authors.forename: Elena
authors.initials: E
authors.lastname: Seoane
authors.forename: Salvador
authors.initials: S
authors.lastname: Resino
authors.forename: Dariela
authors.initials: D
authors.lastname: Micheloud
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: Juan C L Bernaldo
authors.initials: JC
authors.lastname: de Quiros
authors.forename: Raquel
authors.initials: R
authors.lastname: Lorente
authors.forename: Rafael
authors.initials: R
authors.lastname: Rubio
authors.forename: Juan
authors.initials: J
authors.lastname: Gonzalez
authors.forename: Federico
authors.initials: F
authors.lastname: Pulido
authors.forename: José R
authors.initials: JR
authors.lastname: Arribas
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
authors.forename: Má
authors.initials: M
authors.lastname: Muñoz-Fernández
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active; D001059:Apoproteins / Q000097:blood*; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013030:Spain; D016896:Treatment Outcome
chemical_list: D044966:Anti-Retroviral Agents; D001059:Apoproteins; D008055:Lipids